Novel Ex Vivo Culture Method for the Study of Dupuytren’s Disease: Effects of TGFβ Type 1 Receptor Modulation by Antisense Oligonucleotides

Sofia Karkampouna1, Boudewijn PT Kruijhof1, Peter Kloen2, Miryam C Obdeijn2, Annelies MA van der Laan1, Hans J Tanke1, Dwi U Kemaladevi4, Willem MH Hoogaars4, Peter AC ’t Hoen4, Annemieke Aartsma-Rus4, Ian M Clark5, Peter ten Dijke1, Marie-José Goumans1 and Marianna Kruijhof-de Julio1

Dupuytren’s disease (DD) is a benign fibroproliferative disease of the hand. It is characterized by the excessive production of extracellular matrix (ECM) proteins, which form a strong fibrous tissue between the handpalm and fingers, permanently disrupting the fine movement ability. The major contractile element in DD is the myofibroblast (MFB). This cell has both fibroblast and smooth muscle cell-type characteristics and causes pathological collagen deposition. MFBs generate contractile forces that are transmitted to the surrounding collagen matrix. Major profibrotic factors are members of the transforming growth factor-β (TGFβ) pathway which directly regulate the expression levels of several fibrous proteins such as collagen type 1, type 3, and α-smooth muscle actin. Molecular modulation of this signaling pathway could serve as a therapeutic approach. We, therefore, have developed an ex vivo “clinical trial” system to study the properties of intact, patient-derived resection specimens. In these culture conditions, Dupuytren’s tissue retains its three-dimensional (3D) structure and viability. As a novel antifibrotic therapeutic approach, we targeted TGFβ type 1 receptor (also termed activin receptor-like kinase 5) expression in cultured Dupuytren’s specimens by antisense oligonucleotide-mediated exon skipping. Antisense oligonucleotides targeting activin receptor-like kinase 5 showed specific reduction of ECM and potential for clinical application.

Molecular Therapy—Nucleic Acids (2014) 3, e142; doi:10.1038/mtna.2013.69; published online 21 January 2014

Subject Category: Antisense oligonucleotides Therapeutic proof-of-concept

Introduction

Dupuytren’s disease (DD) is a common fibroblastic disorder of the hand, found with high prevalence among Caucasians of Northern European descent.1 This enigmatic benign fibroproliferative disease affecting the connective tissue (Figure 1a) results from a complex interplay of genetic, anatomic, and environmental factors2 with main clinical manifestation being the excessive collagen deposition. A disturbance of the heterogeneous mix of static and dynamic contractile elements located throughout the fascia of the palm and digits can lead to the development of flexion deformities (contracture). Although not associated with high morbidity, the impact on movement ability and quality of life of the patients affected by DD is major. Currently, the common therapy for DD is palmar fasciectomy, which consists of surgical removal of fibrotic tissue and results in immediate improvement of disease. However, due to the high recurrence rate and remanifestation of fibrotic bands, surgery is not a permanent solution.

Several studies have elucidated the etiopathology of DD which is crucial for the design of novel therapies. Uncontrolled wound healing response leads to permanent extracellular matrix (ECM) deposition, e.g., collagen. The cell responsible for ECM production in normal as well as in pathologic conditions is the myofibroblast (MFB) containing both fibroblast and smooth muscle cell-type characteristics.3 MFBs generate contractile forces that are transmitted to the surrounding collagen matrix4 and are distinguished by α-smooth muscle actin (ACTA2) expression. In pathological conditions, ACTA2 expression is persistent.

Major profibrotic factors are members of the transforming growth factor-β (TGFβ) pathway, which directly regulate the expression levels of several intracellular and extracellular fibrous proteins such as COL1A1, COL3A1, and ACTA2.3,5–7 Fibronectin, matrix metalloproteases, and integrins, all of which are aberrantly deregulated in DD,8,9 TGFβ ligands interact with TGFβ type 1 receptor (also termed activin receptor-like kinase 5 (ALK5)/TGFβRI and type 2 (TGFβRII) receptor complexes which subsequently activate by phosphorylation the SMAD2/3, which form heteromeric complexes with SMAD4 and act as downstream transcriptional effectors of the pathway. Activation and transdifferentiation of DD fibroblasts toward MFBs is mainly controlled by TGFβ signaling.10–13 Other cytokines, such as platelet-derived growth factor, are induced by TGFβ14 and also enhance MFB differentiation. TGFβ and platelet-derived growth factor factors are aberrantly activated in DD.14,15,16 In particular, in DD patient-derived MFB cultures, overactive TGFβ signaling causes spontaneous contraction and proliferation.13,15 Contractility is attenuated by inhibiting TGFβ and TGFβ receptor (ALK5) function.15,17,18 We have recently shown that the TGFβ/SMAD and platelet-derived growth factor/
ERK1/2 MAP kinase pathways cooperate in mediating the enhanced proliferation and spontaneous contraction of DD fibroblasts. Inhibiting the uncontrolled fibrotic mechanisms by directly targeting the overactivation of the TGFβ signaling, mediated via its ALK5 receptor, at the molecular level, could be an effective treatment.

A promising approach to deplete the cells from the function of key receptor of TGFβ signaling (ALK5) is by alternative splicing methodology. Particular exon(s) encoding protein domains crucial for protein function can become excluded from the mature messenger RNA (mRNA). Specific antisense oligonucleotides (AON) bind to sites involved in exon splicing to...
the splice sites of a targeted exon and interfere with the splice machinery; therefore, the particular exon is not integrated as part of the mRNA. The resulting mRNA has an intact open reading frame and is translated into a protein which lacks only the particular peptide sequence encoded by the skipped exon. The advantage of this system is that no genetic alterations are introduced, since interference is exclusively with pre-mRNA splicing process. AON methodology has broad therapeutic applicability in many human diseases, particularly in the field of muscular dystrophies with very promising results reported for clinical trials. Based on this principle, we employed the AON-mediated exon skipping technology for disrupting the protein function of the ALK5, targeting in particular the extracellular ligand-binding domain. AONs targeting splice sites of exon encoding extracellular ligand-binding domain (exon 2) of the ALK5 have been developed and tested in vivo (D.U. Kemaladewi et al., unpublished data). This strategy ensures no loss of other important domains of ALK5, such as the transmembrane domain (encoded by exon 3) or serine-threonine kinase activity domain (exon 4-9). ALK5 AON was administered directly to the DD patient-derived specimens by microinjecting it in the center of the tissue, and the effects on fibrosis and ECM deposition were assessed with various imaging and biochemical methods. In this study, we show that DD resected specimens, which are discarded as waste material after surgery, can be maintained viable in defined culture conditions in our novel ex vivo model. Their study can provide us with useful information about the underlying patient-specific pathology and drug response.

Results
Human-derived DD tissue can be maintained under ex vivo culture conditions

Fibroblast derivation from DD specimens requires a long culture period during which cells adapt to culture conditions (plastic surface, high oxygen, and removal of ECM). Such changes of the native microenvironment may result in partial recapitulation of the disease state or fibroproliferative characteristics of the tissue in fibroblast two-dimensional (3D) cultures. We have developed a 3D culture system (Figure 1a,b), which allows human resection specimens to be grown ex vivo (up to 7 days) in defined conditions. Longer culture periods (up to 12 days, data not shown) lead to increased cell death (cleaved caspase 3 positive cells) and absence of proliferation, suggesting nonviability of tissue after a certain time point (day 7). We show that DD resection specimens in the ex vivo “clinical trial” system maintain viability, proliferation (phosphohistone-3), and apoptosis levels (TUNEL) (Figure 1g). As control tissue, we have used normal fascia palmaris from carpal tunnel surgeries, which is not affected by DD. Control tissue was successfully maintained in culture for up to 7 days and is characterized by low levels of proliferation (phosphohistone-3) and apoptosis (TUNEL) (Supplementary Figure S1, upper panel). Histological characterization of the cultured DD biopsies showed that the high expression of fibrotic proteins: ACTA2, COL1A1, and COL3A1 is preserved (Figure 1g, representative images), therefore they recapitulate the in vivo properties. Similar data were obtained from a number of biopsies (normal fascia palmaris, N = 7, DD noncultured tissue, N = 4, and DD tissue after 7 days 3D culture, N = 9) indicating the reproducibility of the method. Quantification of immunofluorescence signal for COL1A1, COL3A1, and ACTA2 (Figure 1d–f), in multiple patient-derived specimens showed that biopsies cultured ex vivo retain the expression characteristics with regards to fibrosis.

Basal expression of ACTA2, COL1A1, and COL3A1 (Figure 1c–g), as well as TGFβ1 and PAI-1 mRNA levels (TGFβ target genes) (Figure 1c), are elevated in both cultured and noncultured DD resection specimens compared to fascia palmaris (control, nonaffected tissue). Moreover, the snap-frozen and the 3D cultured DD (matching) resection specimens similarly show areas of proliferating MFBs and low apoptosis (Figure 1g). All together, the above data indicate that DD tissue under culture conditions remains representative of the disease.

Small molecule inhibitor of TGFβ type 1 receptor kinase (SB-431542) decreases expression of fibrotic proteins in DD specimens

Our novel ex vivo culture method was further used to test the response of the DD tissue to stimulation with different factors directly after fasciectomy procedure. Main profibrogenic stimulus in DD is the TGFβ signaling; consequently, we decided to interfere with the activation status of this particular pathway. Resection specimens (both control (Supplementary Figure S1) and DD (Figure 2a) were treated with TGFβ1 ligand as well as a pharmacological TGFβ type 1 receptor (ALK4, ALK5, ALK7) kinase activity inhibitor (SB-431542). Addition of TGFβ1 to cultured DD specimens resulted in increased expression of target genes ACTA2, COL1A1, and COL3A1 in the majority of individual human samples tested or sustained the high levels (Figure 2b–d). This observation suggests high sensitivity of DD MFB cells to TGFβ, also confirmed by high expression of phosphorylated SMAD2 protein (pSMAD2) (Figure 2a). As expected, treatment with the SB-431542 inhibitor compound in our model suppressed the profibrogenic action of TGFβ and resulted in a trend reduction of the expression of fibrous proteins ACTA2, COL1A1, and COL3A1 (Figure 2). Differential expression levels among individual samples after TGFβ and/or SB-431542 treatments were observed. Proliferation and apoptosis were not significantly affected by the addition of either TGFβ1 or SB-431542 (Figure 2a). Treatment of control tissue with TGFβ cytokine caused an upregulation of ACTA2, COL1A1, and COL3A1 expression (Supplementary Figure S1, middle panel), suggesting a responsiveness of the tissue to the treatment and underlining the profibrotic effect of TGFβ. The above observations may suggest that the 3D ex vivo culture system is suitable for chemical compound screening. Differences in the response of human specimens to growth factor or inhibitor SB-431542 most probably derives from variation among different individuals which can be effectively observed and represented using our ex vivo culture system.

AON-mediated exon skipping of the ALK5

While treatment with SB-431542 resulted in a promising downregulation of fibrotic pathways, this chemical inhibitor blocks the kinase activity of ALK4, ALK5, and ALK7 in a dose-dependent way. Thus, in order to ensure more specificity and less interference with other signaling pathways, we...
have tested a novel strategy to selectively inhibit the function of the ALK5. We used vivo-morpholinos (ViM) based on previously developed AON sequence (D.U. Kemaladewi et al., unpublished data) that selectively target and disrupt the ligand-binding domain of ALK5 by inducing exon skipping of mRNA transcripts. Microinjection (Figure 3a) of resection specimens with fluorescently labeled AON demonstrated efficient uptake (>90%) and transport to the nucleus throughout the tissue (Figure 3b,c). Similarly, the AON targeting ALK5 (ALK5ViM) was microinjected in the centre of the tissues after placing them on the nitrocellular membrane of the transwell culture plates (Figure 3a). At day 3, we validated the skipping of exon 2 by PCR (Figure 3d,e) and verified reduction of full length ALK5 mRNA expression versus the exon skipped mRNA. Full length ALK5 mRNA is decreased by 70–75% during the first 48 hours after AON administration (Supplementary Figure S2a). These data indicate that high rate of exon skipping is achieved at early time points and maintained in the tissue explant cultures. We also determined the collagen expression in different time points and observed a gradual decrease of COL1A1 expression (Supplementary Figure S2b).

ALK5 AON causes a reversal of fibrotic phenotype ex vivo
Constant collagen deposition is the main feature of DD, thus, clinical attempts have been focused on direct induction of collagen degradation in vivo, such as by injectable collagenase treatment.27 Although very promising, this therapeutic approach is associated with several limitations (high morbidity) and cannot completely replace the surgical treatment.28 Our objective was to interfere with the fibrogenic role of TGFβ in a clinically relevant manner. However, TGFβ is a regulator of many crucial processes such as inflammation and would healing in many organs and is secreted by many
Figure 3 Microinjection of antisense oligonucleotides (AONs) in Dupuytren’s disease (DD) resection specimen maintained in three-dimensional (3D) culture and ALK5 exon skipping. (a) AONs coupled to a fluorochrome (AON-fluorescent) were delivered by microinjecting the center of the tissue on the nitrocellulose membrane as described in the cartoon. The tissue was then cultured for 3 days and sectioned in order to determine the presence of nuclei, which had taken up the AON. (b) Direct visualization of the AON-fluorescent (green) and nuclei (TOPRO, blue) in a DD tissue section. (c) Quantification of the percentage of fluorescent cells (AON) relative to total cell count. Scale bars, 50 μm. (d) Description of exon skipping (exon 2) of the ALK5 pre-mRNA. Primer position (exon 1 and exon 3) of primers used for detecting the full length ALK5 and the exon skipped mRNA product are depicted here. (e) DD tissues were cultured and injected with either scrambled (ScrViM) or ALK5ViM. For comparison, treatment with transforming growth factor-β (TGFβ) or SB-431542 compound was also combined with ViM administration. After 3 days of treatments, tissues were homogenized and used for RNA isolation and cDNA synthesis. Touchdown PCR was performed to validate the exon skipping and products were visualized by agarose gel electrophoresis. Full length ALK5 mRNA transcripts were detected in all conditions while exon2-skipped ALK5 mRNA transcripts were only detected in tissues injected with ALK5ViM. CON: untreated condition; SB: treatment with SB-431542 compound; TGFβ: treatment with TGFβ cytokine; TGFβ+SB: treatment with both TGFβ and SB-431542 compound.

Discussion

In the present study, we have developed a novel method for ex vivo analysis of human DD disease and we provide evidence of its suitability for molecular modulation by AONs. AONs were designed to target and inhibit a key profibrotic signaling pathway, which results in significant antifibrotic effects. Given the high risk of recurrence of DD, it would be therapeutically beneficial to reduce local collagen content in order to extend the symptom-free period after surgery, needle fasciotomy, and/or collagenase injection. Our ex vivo “clinical trial” system allows the culture of DD specimens after surgical removal, without the need of fibroblast derivation, or grafting experiments, while preserving the pathological status of the disease by maintaining the complex organization of the ECM and the 3D tissue structure. The main challenges in ex vivo culture methods are viability and preservation of the in vivo normal or pathological traits of the tissue to be studied. Several organ culture and precision cut tissue slice methods have been developed such as the submerged system, the dynamic organ culture, and the gas exchange method. Organ viability, functionality, metabolism, and toxicity can be well studied in all these systems for complex organs such as liver, kidney, intestine, and lungs. A limitation of these methods is the relatively short incubation time possible (~24–72 hours), depending on the tissue origin, as well as the challenge of organ/disease recapitulation. Our methodology is based on an enhanced setup where...
tissue parts are placed continuously and statically in contact with nutrients but are not fully immersed into medium, thus maintaining proper oxygenation and avoiding necrosis in the center of the tissue. Such setup appears suitable for culture of dense tissue such as DD fibrotic parts and facilitates viability for longer periods (up to 7 days tested). Exposure of one side of the tissue to the medium is sufficient for diffusion and absorbance of nutrients throughout the tissue. Small tissue parts (< 200 µm) are preferable in order to allow cell proliferation and longer viability.34 Static incubation was performed, in contrast to most dynamic culture conditions, in order to maintain positional information and cellular sensing.35,36 In addition, this particular setup allows for manipulation (e.g., AON injection) and direct visualization of the effects on the ECM (second harmonic generation). Since DD tissue shows rapid production of ECM proteins, all tissues were cultured in the absence of any exogenous matrix substrates. This is advantageous for the maintenance of native ECM turnover. Moreover, this culture setup is optimal for DD fibrotic tissue due to the content of highly proliferative MFBs and because
the nodules and cords are in vivo quite isolated structures with autonomous characteristics (such as cell/tissue growth and fibrosis). Due to these innate properties, it is likely that the tissues can be maintained ex vivo efficiently.

In this study, we have exclusively utilized the nodule parts, which are the firm thickenings and are considered pathologically very active due to the high content of MFBs. Cord parts are mainly fibroblastic flexions and contain few fibroblasts, which are in a dormant state. It has been proposed that active nodules may progress into cord structures at more advanced stage of the disease, therefore, it is more clinically relevant to target the fibrotic characteristics of the node parts. TGFβ has been found to be expressed in both parts, as well as in the surrounding tissue (appearing not affected by the disease), which may play a role in promoting recurrence of fibrosis as part of wound healing response due to tissue damage from the primary surgery. The majority of the resection specimens we have analyzed using this system respond to TGFβ stimulation by upregulation or maintenance of the expression levels of fibrotic proteins (Figure 2b–d). Decrease in COL1A1 and COL3A1 but not of ACTA2 has been detected in two biopsies after TGFβ stimulation, which may suggest the function of a negative feedback loop due to high levels of TGFβ. Interestingly, when DD biopsies were treated with SB-431542 inhibitor, expression of collagen and ACTA2 was decreased in the majority of biopsies or sustained the same levels as if untreated (Figure 2b–d).

Previous studies have attempted manipulation of TGFβ by neutralizing antibodies and kinase inhibitors. TGFβ has been also targeted in indirect ways such as by cyclic AMP, angiotensin inhibitors, tamoxifen, and administration of bone morphogenetic protein-6. Given the pleiotropic effect of TGFβ signaling, the aim is to normalize and not completely abolish its function. Therefore, in order to restore the balance of pathway activation without fully disrupting its function, we have selectively inhibited the ALK5-mediated profibrotic pathway by exon skipping technology. It is worth noting that AON approach provides the advantage of high specificity exclusively for ALK5 mRNA (exon 2 encoding ligand-binding domain), while the SB-431542 compound targets activity of three kinase receptors (ALK4, ALK5, and ALK7), all implicated in the activin/TGFβ pathway. Moreover, SB-431542 may not block TGFβ/ALK5-induced non-SMAD signaling, whereas ALK5 AON will inhibit both pathways. TGFβ/p38 and ERK MAP kinases have been shown to be involved in fibroproliferative response in DD. Delivery of ALK5 AON by affecting SMAD and non-SMAD TGFβ signaling may thus achieve better inhibition than ALK5 kinase inhibitors by interfering with multiple pathways downstream of ALK5. Compared to regular oligonucleotides, small molecule inhibitors have better pharmacokinetic properties, due to the short half-lives and inability to efficiently cross tissue membranes. However, currently, there are many oligonucleotide modifications available that ensure improved stability, serum half-life, and uptake of oligonucleotides. Our studies here use ViMs, which are antisense phosphorodiamidate morpholino oligomers covalently linked to a molecular scaffold that carries a guanidinium group at each of its eight tips to enhance delivery, to show proof-of-concept for this approach. Efficacy of ViMs has also been shown by others in animal models. However, further clinical development of this particular compound is hampered by toxic effects. Nevertheless, there is a plethora of chemical modifications available that can be studied further for clinical development. In light of this, it is encouraging that we were able to obtain similar results with ALK5 AONs of the 2′-O-methyl phosphorothioate AON chemistry (Supplementary Figure S4), which is very similar to the chemistry approved by US Food and Drug Administration ( mipomersen) and identical to drisapersen, which is in phase 3 clinical trials for Duchenne muscular dystrophy. TGFβ secretion might also play a significant role in the recurrence of fibrosis after surgical removal. In this context, a hypothetical therapeutic setting would be the administration of AONs prior to or instead of the surgical intervention to counteract the TGFβ signaling in the remaining MFBs.

A challenge in the field of Dupuytren’s is the lack of in vivo modeling of the disease. Here, we have developed a very robust and reproducible ex vivo 3D culture method with a simple setup (no growth factors or matrix protein support required). By using the ALK5ViM AON in this system, we have showed significant decrease in collagen protein expression and degradation/reorganization of collagen structures. Excessive collagen production is the main clinical symptom in this disease and here we provide proof of decrease in collagen deposition ex vivo. The average reduction of full length ALK5 mRNA achieved was 70–75% within the first 48 hours (Supplementary Figure S2a) and about of 30–60% by day 3 (Figure 4b; Supplementary Figure S2a). Our data indicate the potential of MFBs to reverse into a less fibrotic phenotype and to respond to growth factor inhibition even after advanced disease progression. In addition, we show the feasibility of a well-established ex vivo imaging approach, such as the second harmonic generation, for the study of ECM structure in native unstained tissue which to our knowledge has not been previously used for DD. The above observations may change the view of therapeutic approaches currently used for DD. Ultimately, the ex vivo “clinical trial” system can be applied for individualized therapy research after tissue resection as a drug screening method to test for specific responsiveness of DD tissues to a panel of growth factors and inhibitors and eventually lead to targeted therapy in case of recurrence.

Materials and methods

Generation of 3D culture system. Specimens from DD surgeries are equally sliced and placed in transwell plates onto 0.4 μm nitrocellulose membranes (Greiner Bio One, Alphen aan den Rijn, the Netherlands) in defined culture conditions (Dulbecco’s modified Eagle’s medium, with 1% fetal calf serum, 1% penicillin-streptomycin) and allowed to grow (7 days). Nutrient exchange occurs by diffusion from the medium through the membrane while DD tissue remains continuously in contact with the liquid but is not immersed. Tissue resection specimens (N = 9 DD and N = 4 normal fascia palmaris) were treated with a combination of activators and inhibitors of the TGFβ signaling pathway (e.g., TGFβ, 5ng/ml; SB-431542, 10ng/ml, Tocris). After culture, tissues were processed for RNA isolation or were fixed in 4% paraformaldehyde, incubated in 30% sucrose buffer, embedded in Tissue Tek-O.C.T. compound and stored at −80 °C.
**Antisense oligonucleotides.** The AONs used to target ALK5 were developed and recently described in another study, in which *in vitro* and *in vivo* efficiency of the different AONs was extensively tested in the context of muscular dystrophies (D.U. Kemaladewi *et al.*, unpublished data). In short, the AONs targeting ALK5 specifically bind to and induce exon skipping of exon 2 of the ALK5 precursor mRNA transcript. Exon 2 encodes for the ligand-binding domain, which is, together with the type 2 receptor, essential in capturing the ligand to initiate signalling. Exclusion of exon 2 will generate a transcript with intact open reading frame, but the resulting protein will lack the ligand binding domain and is therefore functionally impaired. Vivo-morpholino AONs with a morpholino backbone and an octaguanidine moiety to enhance cellular uptake were used in this study since they have been shown to increase exon skipping efficiency in animal models.50 ViM AONs (0.5 and 1 nmol, Genetools, Philomath, OR) were diluted in 1% fetal bovine serum-Dulbecco’s modified Eagle’s medium or phosphate-buffered saline and were microinjected in the tissue. The sequences (5′-3′) of the ViM AONs are the following: ALK5ViM: GCAGTGGTCCTGATTG-3′-O-methyl ribose, ScrViM: CCTCTTACCTCAGTTAC AATTTATA.

AONs are the following: ALK5ViM: GCAGTGGTCCTGATTG-3′-O-methyl ribose AONs with phosphorothioate modifications. The authors declare no conflict of interest.

**Materials and Methods**

**Figure S1.** Normal fascia palmaris tissue cultures in the 3D ex vivo “clinical trial” system.

**Figure S2.** Time course of *ex vivo* delivery of ALK5 ViM AON.

**Figure S3.** Quantification of pSMAD2 immunofluorescence by image analysis.

**Figure S4.** *Ex vivo* delivery of ALK5 AON with ViM and 2′OMe chemical backbones.

RNA isolation, reverse transcription polymerase chain reaction, and quantitative polymerase chain reaction. See Supplementary Materials and Methods for details.

Microscopy and image analysis. See Supplementary Materials and Methods for details.

Immunofluorescence. See Supplementary Materials and Methods for details.

Acknowledgments. This study was supported by Netherlands Organization for Scientific Research (NWO-MW), Netherlands Institute for Regenerative Medicine, Cancer Genomics Centre and Netherlands Centre for Biomedical Genetics. The authors declare no conflict of interest.

**Supplementary material**

**Figure S1.** Normal fascia palmaris tissue cultures in the 3D ex vivo “clinical trial” system.

**Figure S2.** Time course of *ex vivo* delivery of ALK5 ViM AON.

**Figure S3.** Quantification of pSMAD2 immunofluorescence by image analysis.

**Figure S4.** *Ex vivo* delivery of ALK5 AON with ViM and 2′OMe chemical backbones.
17. Tse, R, Howard, J, Wu, Y and Gan, BS (2004). Enhanced Dupuytren’s disease fibroblast population collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 5: 41.

18. Verjee, LS, Verhoeek, JS, Chan, JK, Krausgruber, T, Nicolaïdou, V, Izadi, D et al. (2013). Unveiling the signal transduction pathway responsible for Dupuytren’s disease reveals TNF-alpha a therapeutic target. Proc Natl Acad Sci USA 110: E828–E837.

19. Aartssen-Rus, A, van Vliet, L, Hirschi, M, Janson, AA, Heemskerk, H, de Winter, C et al. (2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17: 548–553.

20. Aartssen-Rus, A, Bremmer-Bout, M, Janson, AA, den Dunnen, JG, van Ommen, GJ and van Deutekom, JC (2002). Testing exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12 (suppl. 1): S71–S77.

21. Goemans, NM, Tulinius, M, van den Akker, JT, Ulinius, M, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PPRO01 in Duchenne’s muscular dystrophy. N Engl J Med 364: 1513–1522.

22. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Guglielmi, K, Anthony, K et al. (2003). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 359: 595–605.

23. Vellucci, VF and Reiss, M (1997). Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene. Genomics 46: 278–283.

24. Guillouzo, A, Morel, F, Ratanasawang, D, Cheone, C and Guguen-Guillouzo, C (1990). Long-term culture of functional hepatocytes. Toxicol In Vitro 4: 415–427.

25. O’Gorman, DB, Wu, Y, Seney, S, Zhu, RD and Gan, BS (2006). Wnt expression is not by blunting TGF-beta signalling. J Cell Mol Med 10: 157–165.

26. Goemans, NM, Tulinius, M, van den Akker, JT, Ulinius, M, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PPRO01 in Duchenne’s muscular dystrophy. N Engl J Med 364: 1513–1522.

27. Gilpin, D, Coleman, S, Hall, S, Houston, A, Karrasch, J and Jones, N (2010). Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am 35: 2–11.

28. Witthaut, J, Jones, G, Skrepnik, N, Kushner, H, Houston, A and Lindau, TR (2013). Efficacy and safety of collagenase clostridium histolyticum injection in Dupuytren’s disease. J Hand Surg Am 38: 10–17.

29. Kuhn, MA, Payne, WG, Kierney, PC, Pu, LL, Smith, PD, Siegler, K et al. (2002). N-acetylcycteine abrogates fibrogenic properties of fibroblasts isolated from diabetic mice by blunting TGF-beta signalling. J Cell Mol Med 6: 157–165.

30. Kopp, J, Seyhan, H, Müller, B, Lanczak, J, Pausch, E, Gressens, AM et al. (2006). TGF-beta receptor kinase activity in mesangial Cells. J Biochemical 284: 22285–22296.

31. van de Bovenkamp, M, Groothuis, MT, Draaisma, AL, Merema, MT, Bezuijen, J, van Gils, MJ et al. (2005). Precision-cut liver slices as a new tool to study toxicity-induced hepatic steatoce cell activation in a physiologic milieu. Toxicological Sciences 85: 635–648.

32. Bisson, MA, McGrouther, DA, Madera, V and Grobbee, A (2003). The different characteristics of Dupuytren’s disease fibroblasts derived from either nodule or cord: expression of v-smooth muscle actin and the response to stimulation by TGF-β1. The Journal of Hand Surgery: British & European Volume 28: 351–356.

33. Townley, WA, Baker, R, Sheppard, N and Grobbee, A (2006). Dupuytren’s contracture unfolded. BMJ: 332: 397–400.

34. Tse, R, Howard, J, Wu, Y and Gan, BS (2004). Enhanced Dupuytren’s disease fibroblast population collagen lattice contraction is independent of endogenous active TGF-beta2. BMC Musculoskelet Disord 5: 41.

35. Groth, M, Gortz, GMM, Meijer, KDF and Olinga, P (2008). Liver slices as a new model to study toxicity-induced hepatic steatoce cell activation in a physiologic milieu. Toxicological Sciences 85: 635–648.

36. Olinga, P, Groen, K, Hof, H, De Kantor, R, Koster, H, Leeman, WR et al. (2001). Comparison of five incubation systems for rat liver slices using functional and viability parameters. J Pharmacol Toxicol Methods 38: 59–69.

37. de Vos, IA, Olinga, P, De Jager, MB, Merema, MT, Bezuijen, J, van Gils, MJ et al. (2005). Precision-cut liver slices as a new tool to study toxicity-induced hepatic steatoce cell activation in a physiologic milieu. Toxicological Sciences 85: 635–648.

38. de Graaf, IA, Olinga, P, De Jager, MB, Merema, MT, Bezuijen, J, van Gils, MJ et al. (2005). Precision-cut liver slices as a new tool to study toxicity-induced hepatic steatoce cell activation in a physiologic milieu. Toxicological Sciences 85: 635–648.

39. Fisher, R, Urech, JR, Nakanoto, PZ and Brendel, K (2001). Histological and biochemical evaluation of precision-cut liver slices. Toxicology Mechanisms and Methods 11: 59–79.

40. Vogel, V and Sweeney, PA (2006). Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol 7: 265–275.

41. Saleh, AF, Arzumanov, AA and Gait, MJ (2012). Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol Biol 867: 365–378.

42. Stein, EA, Dufour, R, Gagne, C, Gaudet, D, East, C, Donovan, JM et al. (2012). Allosteric inhibitors of the TGF-β receptor type I: new chemistries for exon skipping. J Mol Med-Berlin 90: 53–63.

43. Kopp, J, Seyhan, H, Müller, B, Lanczak, J, Pausch, E, Gressens, AM et al. (2006). TGF-beta receptor kinase activity in mesangial Cells. J Biochemical 284: 22285–22296.